EUVIMEDFaigh amach EUVIMED
Open access · CC BY 4.0

Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category

Juan Morote iD, Marina Triquell, Miriam Campistol iD, José M Abascal, Pol Servian, Enrique Trilla iD

BJUI Compass · 2023-05 · 4 (3) · 266-268

DOI: 10.1002/bco2.211 ↗

At a glance

Journal article in BJUI Compass, published online on 2022-12-28. Written by Juan Morote and 5 co-authors. Institution: Department of Urology Vall d'Hebron Hospital Barcelona Spain. Cited 5 times so far (Crossref); 8 references. The full text is freely available (open access, CC BY 4.0).

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

After the U.S. Preventive Task Force recommended against screening for prostate cancer (PCa), the early detection of PCa has moved towards clinically significant PCa (csPCa), reducing the number of unnecessary prostate biopsies and the overdetection of insignificant PCa. This paradigm change is a result of the spread of multiparametric magnetic resonance imaging (mpMRI), which has a high negative predictive value for csPCa and allows guided biopsies to be performed on detected lesions with a prostate imaging-report and data system (PI-RADS) score ≥3.1 However, suspicion of PCa is still based on serum prostate-specific antigen (PSA) elevation and/or abnormal digital rectal examination (DRE), and the demand for mpMRI exams has increased to the extent that it is no longer affordable in many centres.2 The European Association of Urology (EAU) currently recommends the use of risk-organised models for the early detection of csPCa, stratifying the initial PCa suspicion to avoid unnecessary mpMRI exams and subsequent biopsies.2 At experienced centres, mpMRI will be substituted with biparametric MRI, reducing the scan time fourfold while maintaining the quality and reproducibility of PI-RADS.3 PSA density (PSAD) has been proposed to avoid unnecessary biopsies after mpMRI and also to avoid unnecessary mpMRIs.4 It has been proposed that PSA density (PSAD) should be used to avoid unnecessary mpMRIs and subsequent biopsies.4 Prostate volume is usually unknown at the time of PCa suspicion; it should therefore be assessed using the DRE category because transrectal ultrasound (TRUS) is not usually performed to assess prostate volume outside of the prostate biopsy procedure.5 Roobol et al.6 proposed that, where TRUS measurement is not available, DRE should be used to estimate prostate volume for the Rotterdam risk calculator. Additionally, there is evidence that men with PSA > 10 ng/ml and abnormal DRE do not benefit from mpMRI and guided biopsies; these men should therefore be directly scheduled for TRUS systematic prostate biopsies.7 We intend to analyse the effectiveness of sequencing the stratification of men with suspected PCa according to their serum PSA levels and DRE, and thereafter according to the PSAD based on their DRE prostate volume category (PSAD-DRE), to avoid mpMRI exams. We retrospectively analysed a multicentre dataset of 2881 correlative men with suspected PCa, based on PSA > 3.0 ng/ml and/or abnormal DRE. After pre-biopsy 3-Tesla mpMRI, those with lesions with a PI-RADS v.2 score ≥ 3 were scheduled for 2- to 4-core transrectal ultrasound (TRUS) cognitively guided biopsies and 12-core TRUS systematic biopsies. Those with a PI-RADS v.2 score 10 ng/ml and abnormal DRE on initial assessment, 264 cases of csPCa (87.4% of the subset) were detected using the systematic biopsies described above.7 In the remaining 2579 men, PSAD-DRE was calculated from the median MRI prostate volume of the corresponding range of DRE prostate volume categories. Category I corresponded to small prostates with less than 30 ml, which were detected in 321 men (12.4%) been 25 ml the median MRI prostate volume. Category I corresponded to small prostates (i.e.,

Subjects

Author keywords

clinically significantearly detectionmagnetic resonance imagingprostate cancersuspicion

Authors and institutions

  • Department of Urology Vall d'Hebron Hospital Barcelona Spain.
  • Department of Surgery Universitat Autòmoma de Barcelona Barcelona Spain.
  • Department of Urology Parc de Salut Mar Barcelona Spain.
  • Department of Surgery Universitat Pompeu Fabra Barcelona Spain.
  • Department of Urology Germans Trias i Pujol Hospital Badalona Spain.

ORCID profiles: Juan Morote, Miriam Campistol, Enrique Trilla

Cite

APA

Morote, J., Triquell, M., Campistol, M., Abascal, J. M., Servian, P., & Trilla, E. (2023). Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category. BJUI Compass, 4(3), 266-268. https://doi.org/10.1002/bco2.211

Vancouver

Morote J, Triquell M, Campistol M, Abascal JM, Servian P, Trilla E. Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category. BJUI Compass. 2023;4(3):266-268. doi:10.1002/bco2.211

BibTeX
@article{Morote2023,
  author = {Morote, Juan and Triquell, Marina and Campistol, Miriam and Abascal, José M and Servian, Pol and Trilla, Enrique},
  title = {Stratifying the initial prostate cancer suspicion to avoid magnetic resonance exams by sequencing men according to serum prostate‐specific antigen, digital rectal examination and the prostate‐specific antigen density based on digital rectal prostate volume category},
  journal = {BJUI Compass},
  year = {2023},
  volume = {4},
  number = {3},
  pages = {266--268},
  doi = {10.1002/bco2.211}
}
Start for free →